HCV #msg-34747018 InterMune Reports Results from Triple Combination Study of ITMN-191 #msg-33270432 (AASLD Poster) HCV NS3 helicase inhibitor screening #msg-33270394 (AASLD Poster) phenotypic analysis of NS3 sequences #msg-33270382 (AASLD Poster) ITMN-191 (R7227) with the Active Moiety of the NS5B Inhibitors #msg-33270355(AASLD Poster) PK-PD for ITMN-191 in a Phase 1 MAD #msg-33270341 (AASLD Poster) ITMN-191 Phase 1b #msg-33270294 (AASLD Poster) ITMN-191 Phase 1A #msg-33270262 (AASLD Poster) ITMN-5489 #msg-33446127 INFORM-1 Trial Initiation #msg-33497987 INFORM-1 Study information (from DB webcast) #msg-33967428 INFORM-1 clinical trials.gov info
IPF #msg-35288566 CAPACITY Trial Results PR #msg-34138706 Shionogi announced the launch of Pirespa (Pirfenidone) #msg-33518800 Differences between Shionogi Phase 3 and CAPACITY (Pirfenidone Phase 3) #msg-32898098 Shionogi received marketing approval
Financials 154.7 Million (End of Q4) + 63.5 million 2/09 Financing 170 Debt (2 convertibles 85 million due March ’11 convert price $21.63 other 85 million due March ’15 convert price $18.88)
43.5 million shares outstanding (not counting oconverts – 8.432 million shares and options 5.077 million)
Upcoming Events Q2 2009 (EASL): Present ITMN-191 Phase 1b triple combination study results Q2 2009 (EASL): Present top-line results of available cohorts from INFORM-1 Q2 2009 (ATS): Present Pirfenidone results Summer ’09: Roche to initiate Phase 2B study with ITMN-191 (R7227) Summer ’09: Submit NDA to FDA for Pirfenidone Q4 2009 (AASLD): Presentation of all cohorts of INFORM-1 End ’09: Submit NDA to MAA for Pirfenidone Q4 ‘09/Q1 ’10: RVR data from 12 week cohort of Phase 2B R7227 study Mid ’10: File IND for ITMN-520 (Pirfenidone Analog)
Market Data 
Markets 
AI
